drugset
drugset / Trial / NCT02875678

A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

NCT02875678 ↗

Phase 1 Terminated 4 enrolled Abide Therapeutics
RandomizedCrossoverTriple-blindBasic science

Summary

A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients with Functional Dyspepsia.

Timeline

Start
2016-11-22
Primary completion
2017-08-07
Completion
2017-08-07

Outcome

Outcome not reported

Stopped (Enrollment): “recruitment challenges”

Drugs

EvaluationDrugModalityDoseRoute
Subject ABX-1431 Small molecule 40 mg —

Indications

dyspepsia